Abstract
The current therapy for ovarian cancer has advanced from alkylating agents, to a combination of carboplatinum and paclitaxel offering increased survival. Although most patients respond to this first-line therapy, initially, the majority of these patients relapse within 2 years. The mechanisms responsible for acquired drug resistance in ovarian cancer have been elucidated only in part. They include i) enhanced drug export, ii) activation/inhibition of intracellular signalling pathways, iii) molecular alterations in tubulin isotype composition. A better understanding of these mechanisms is needed, in order to develop new approaches, aimed at overcoming resistance to anticancer agents, and to reveal the complexity of causes, which contribute to drug resistance. In this review we offer an updated overview of proteomic studies on the molecular mechanisms of paclitaxel resistance. These proteomic studies also identify potential targets for modulating drug resistance, that could be predictive of response to chemotherapy in ovarian carcinomas.
Keywords: Anticancer drugs, mass spectrometry, ovarian cancer, paclitaxel, proteomics, two-dimensional electrophoresis
Current Cancer Drug Targets
Title:The Impact of Proteomics in the Understanding of the Molecular Basis of Paclitaxel-Resistance in Ovarian Tumors
Volume: 12 Issue: 8
Author(s): D. Vergara, A. Tinelli, A. Iannone and M. Maffia
Affiliation:
Keywords: Anticancer drugs, mass spectrometry, ovarian cancer, paclitaxel, proteomics, two-dimensional electrophoresis
Abstract: The current therapy for ovarian cancer has advanced from alkylating agents, to a combination of carboplatinum and paclitaxel offering increased survival. Although most patients respond to this first-line therapy, initially, the majority of these patients relapse within 2 years. The mechanisms responsible for acquired drug resistance in ovarian cancer have been elucidated only in part. They include i) enhanced drug export, ii) activation/inhibition of intracellular signalling pathways, iii) molecular alterations in tubulin isotype composition. A better understanding of these mechanisms is needed, in order to develop new approaches, aimed at overcoming resistance to anticancer agents, and to reveal the complexity of causes, which contribute to drug resistance. In this review we offer an updated overview of proteomic studies on the molecular mechanisms of paclitaxel resistance. These proteomic studies also identify potential targets for modulating drug resistance, that could be predictive of response to chemotherapy in ovarian carcinomas.
Export Options
About this article
Cite this article as:
Vergara D., Tinelli A., Iannone A. and Maffia M., The Impact of Proteomics in the Understanding of the Molecular Basis of Paclitaxel-Resistance in Ovarian Tumors, Current Cancer Drug Targets 2012; 12 (8) . https://dx.doi.org/10.2174/156800912803251171
DOI https://dx.doi.org/10.2174/156800912803251171 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Current Medicinal Chemistry Anti-HER2 Cancer Therapy and Cardiotoxicity
Current Pharmaceutical Design Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response
Anti-Cancer Agents in Medicinal Chemistry Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy A Review of Ensemble Methods in Bioinformatics
Current Bioinformatics Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications
Current Medicinal Chemistry Ligament and Tendon Repair through Regeneration Using Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Folate Receptor Targeted Liposomes
Drug Design Reviews - Online (Discontinued) Gene Delivery for Cancer Therapy
Current Drug Delivery Targeting: The ADEPT Story So Far
Current Drug Targets Exploring the Synthesis and Anticancer Potential of L-Tyrosine-Platinum(II) Hybrid Molecules
Medicinal Chemistry Activatable Optical Probes for the Detection of Enzymes
Current Organic Synthesis EDITORIAL [Hot Topic: Endometriosis and Women’s Health (Guest Editor: Angelos Daniilidis)]
Current Women`s Health Reviews Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets